These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 23381694

  • 1. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS.
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
    [Abstract] [Full Text] [Related]

  • 2. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
    Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.
    J Clin Oncol; 2013 May 10; 31(14):1740-7. PubMed ID: 23569308
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 10; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 4. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
    Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.
    Cancer; 2012 Nov 15; 118(22):5709-18. PubMed ID: 22786751
    [Abstract] [Full Text] [Related]

  • 5. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA, Nathan F, Taboada M, Morris T, Hubner A.
    Prostate; 2011 Sep 15; 71(12):1264-75. PubMed ID: 21271613
    [Abstract] [Full Text] [Related]

  • 6. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C.
    Lancet Oncol; 2013 Nov 15; 14(12):1193-9. PubMed ID: 24075621
    [Abstract] [Full Text] [Related]

  • 7. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
    Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R.
    Invest New Drugs; 2011 Feb 15; 29(1):118-25. PubMed ID: 19763400
    [Abstract] [Full Text] [Related]

  • 8. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
    James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA.
    BJU Int; 2010 Oct 15; 106(7):966-73. PubMed ID: 20840318
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
    Wu Y, Shao N, Shen ZX, Li Q, Wang Y, Li C, Ma G, Dong J, Lu XJ, Feng NH.
    Eur Rev Med Pharmacol Sci; 2014 Oct 15; 18(21):3291-6. PubMed ID: 25487941
    [Abstract] [Full Text] [Related]

  • 10. Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
    Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H.
    Xenobiotica; 2012 Apr 15; 42(4):363-71. PubMed ID: 22014279
    [Abstract] [Full Text] [Related]

  • 11. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
    Qi P, Chen M, Zhang LX, Song RX, He ZH, Wang ZP.
    PLoS One; 2015 Apr 15; 10(7):e0133803. PubMed ID: 26192308
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2010 Apr 15; 105(8):1074-81. PubMed ID: 22129214
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.
    Eur J Cancer; 2014 Jun 15; 50(9):1602-9. PubMed ID: 24725337
    [Abstract] [Full Text] [Related]

  • 17. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
    Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R.
    J Clin Oncol; 2011 Nov 01; 29(31):4129-36. PubMed ID: 21969509
    [Abstract] [Full Text] [Related]

  • 18. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).
    Dawson N, Payne H, Battersby C, Taboada M, James N.
    J Cancer Res Clin Oncol; 2011 Jan 01; 137(1):99-113. PubMed ID: 20390429
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
    Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M.
    J Clin Oncol; 2009 Nov 10; 27(32):5431-8. PubMed ID: 19805692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.